| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
867,229 |
| 52
Week Range: |
$187.64 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
19,405 |
57,754 |
513,978 |
| Total Sell Value |
$0 |
$4,136,219 |
$11,851,618 |
$91,955,621 |
| Total People Sold |
0 |
2 |
7 |
9 |
| Total Sell Transactions |
0 |
2 |
21 |
74 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Romp Charles R |
EVP, Commercial |
• – – |
2022-04-20 |
4 |
AS |
$144.32 |
$46,038 |
D/D |
(319) |
49,816 |
|
8% |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2022-04-20 |
4 |
AS |
$144.32 |
$57,872 |
D/D |
(401) |
75,946 |
|
8% |
|
| Siegall Clay B |
President & CEO |
• • – |
2022-04-20 |
4 |
AS |
$144.32 |
$272,041 |
D/D |
(1,885) |
666,060 |
|
8% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2022-04-20 |
4 |
AS |
$144.32 |
$81,829 |
D/D |
(567) |
127,891 |
|
8% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2022-04-20 |
4 |
AS |
$144.32 |
$82,839 |
D/D |
(574) |
59,064 |
|
8% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2022-04-20 |
4 |
AS |
$144.32 |
$113,579 |
D/D |
(787) |
77,627 |
|
8% |
|
| Gryska David W |
Director |
– • – |
2022-04-19 |
4 |
AS |
$143.32 |
$575,783 |
D/D |
(4,000) |
46,250 |
|
9% |
|
| Gryska David W |
Director |
– • – |
2022-04-19 |
4 |
OE |
$20.06 |
$80,240 |
D/D |
4,000 |
46,940 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2022-04-07 |
4 |
AS |
$151.42 |
$2,628,610 |
D/D |
(17,043) |
667,945 |
|
8% |
|
| Siegall Clay B |
President and CEO |
• • – |
2022-04-07 |
4 |
OE |
$26.10 |
$444,822 |
D/D |
17,043 |
668,419 |
|
- |
|
| Baker Bros. Advisors (gp) Llc |
Director |
– • • |
2022-03-08 |
4 |
OE |
$20.06 |
$702,100 |
I/I |
35,000 |
42,965,004 |
|
- |
|
| Siegall Clay B |
President & CEO |
• • – |
2022-03-07 |
4 |
AS |
$132.72 |
$2,289,655 |
D/D |
(17,043) |
667,945 |
|
33% |
|
| Siegall Clay B |
President & CEO |
• • – |
2022-03-07 |
4 |
OE |
$26.10 |
$444,822 |
D/D |
17,043 |
671,945 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2022-03-03 |
4 |
AS |
$126.98 |
$1,524,558 |
D/D |
(12,000) |
59,500 |
|
40% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2022-03-03 |
4 |
OE |
$26.10 |
$313,200 |
D/D |
12,000 |
60,657 |
|
- |
|
| Simonian Nancy A |
Director |
– • – |
2022-03-02 |
4 |
OE |
$20.04 |
$501,000 |
D/D |
25,000 |
52,500 |
|
- |
|
| Siegall Clay B |
President & CEO |
• • – |
2022-02-07 |
4 |
AS |
$137.29 |
$2,385,566 |
D/D |
(17,043) |
667,945 |
|
4% |
|
| Siegall Clay B |
President & CEO |
• • – |
2022-02-07 |
4 |
OE |
$26.10 |
$444,822 |
D/D |
17,043 |
668,245 |
|
- |
|
| Gryska David W |
Director |
– • – |
2022-02-07 |
4 |
AS |
$137.45 |
$624,441 |
D/D |
(4,500) |
46,250 |
|
4% |
|
| Gryska David W |
Director |
– • – |
2022-02-07 |
4 |
OE |
$20.06 |
$90,270 |
D/D |
4,500 |
48,621 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2022-02-03 |
4 |
AS |
$136.14 |
$95,706 |
D/D |
(703) |
78,244 |
|
7% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2022-02-02 |
4 |
AS |
$137.58 |
$101,672 |
D/D |
(739) |
78,947 |
|
2% |
|
| Gryska David W |
Director |
– • – |
2022-01-28 |
4 |
AS |
$121.69 |
$551,539 |
D/D |
(4,500) |
46,250 |
|
13% |
|
| Gryska David W |
Director |
– • – |
2022-01-28 |
4 |
OE |
$20.06 |
$90,270 |
D/D |
4,500 |
46,464 |
|
- |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,915 |
76,347 |
|
- |
|
1805 Records found
|
|
Page 8 of 73 |
|
|
